Fluprostenol is a PGF2αR (prostaglandin F (FP) receptor) agonist that is more selective than PGF2α (sc-201227). The compound can activate phosphorylation of ERK 2 (extracellular signal-regulated kinase (ERK)), p38-Mitogen-activated protein kinase (MAPK) and JNK3 (c-Jun N-terminal kinase (JNK)) in rat aortas. Studies have shown that it can induce phospholipase C and Ca+ mobilization in human myometrial cells and can decrease intraocular pressure (IOP) by improving aqueous humor outflow through the trabecular meshwork (TM) via inhibition of endothelin (ET)-1-dependent mechanisms. Fluprostenol also suppresses the expression of adipogenic genes in 3T3-L1 cells.
1. Dukes, M., et al. 1974. Nature. 250: 330-331. PMID: 4853720
2. Carrasco, M.P., et al. 1996. J. Clin. Endocrinol. Metab. 81: 2104-2110. PMID: 8964835
3. Thieme, H., et al. 2006. Invest. Ophthalmol. Vis. Sci. 47: 938-945. PMID: 16505027
4. Rice, K.M., et al. 2010. Ann. Clin. Lab. Sci. 40: 26-31. PMID: 20124327
Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2019 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.